The global interventional cardiology devices market is expected to reach USD 25.16 billion by 2020, according to a new report by Grand View Research. Increasing prevalence of cardiovascular diseases coupled with adoption of minimally invasive surgeries is expected to boost the interventional cardiology device market over the forecast period. Unhealthy lifestyle habits such as high alcohol consumption, smoking, and lack of physical exercise are triggering incidences of cardiovascular diseases. Furthermore, the number of congenital heart disease patients is on a constant rise and this acts as a growth driver for the market.
To request a sample copy or view summary of this report, click the link below:
According to a report published by the U.S. CDC (Centers for Disease Control and Prevention) in 2011, congenital heart defects are the most common birth defects in the U.S., affecting approximately 1% of the births every year. The treatment of cardiovascular disorders has changed dramatically due to the introduction of new drug therapies and devices such as guidewires and stents allowing the patient to live better quality and longer lives.
The advent of technologically advanced internal substitutes plays an integral role in this market and manufacturers focus on developing new products to curb problems associated with previous versions. For example, the evolution of stents began from bare metal stents and has now reached a completely new horizon in the form of disappearing stents (bio-absorbable stents). Stents accounted for over 70% market share primarily owing to high usage rates in 2013.
Catheters in sync with stent are expected to register steady growth to reach up to a market size of over USD 2.5 billion in 2020. The growth is primarily driven by primarily the rising demand for minimally invasive medical procedures in the field of cardiovascular diseases. Faster patient recovery time and lesser procedure duration are two most significant factors contributing towards the rising demand of these medical procedures.
The North America interventional cardiology device market in 2013 was valued at over USD 5.5 billion, owing to factors such as the presence of favorable government initiatives encouraging new product development, sophisticated healthcare infrastructure and increasing patient awareness levels coupled with relatively higher healthcare expenditures in the region.
On the other hand, the Asia Pacific market is expected to reach over USD 6.4 billion by 2022, growing at a lucrative rate over the forecast period. The growth is attributed to the presence of large untapped opportunities, rising healthcare expenditure, cardiovascular disease incidence rate, and disposable income levels. Prominent players operating in this industry includes Cordis Corporation, Abbott Laboratories, Medtronic, Inc, Terumo Medical Corporation, B. Braun Melsungen AG, and Boston Scientific.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.